Arginine vasopressin in mood disorders: A potential biomarker of disease pathology and a target for pharmacologic intervention

Psychiatry and Clinical Neurosciences, Journal Year: 2024, Volume and Issue: 78(9), P. 495 - 506

Published: June 25, 2024

Vasopressin or arginine‐vasopressin (AVP) is a neuropeptide molecule known for its antidiuretic effects and serves to regulate plasma osmolality blood pressure. The existing literature suggests that AVP plays multifaceted—though less well‐known—role in the central nervous system (CNS), particularly relation pathophysiology treatment of mood disorders. Animal models have demonstrated implicated regulating social cognition, affiliative prosocial behaviors, aggression, often conjunction with oxytocin. In humans, disorders through on hypothalamic–pituitary–adrenal (HPA) axis as well serotoninergic glutamatergic systems. Measuring has yielded interesting but mixed results stress‐related Recent advances led development copeptin stable reliable surrogate biomarker AVP. Another relatively unexplored issue interaction between osmoregulatory disorder pathophysiology, given psychotropic medications cause dysregulation receptor expression signaling can subsequently lead clinical syndromes like syndrome inappropriate diuresis diabetes insipidus. Finally, pharmaceutical trials agents act V1a V1b antagonists are still underway. This narrative review summarizes: (1) neurobiology vasopressinergic CNS; (2) monoaminergic pathways disorders; (3) iatrogenic caused by medications; (4)

Language: Английский

---

A cross talk on the role of contemporary biomarkers in depression

Biomarkers, Journal Year: 2024, Volume and Issue: 29(1), P. 18 - 29

Published: Jan. 2, 2024

Biomarkers can be used to identify determinants of response various treatments mental disorders. Evidence date demonstrates that markers inflammatory, neurotransmitter, neurotrophic, neuroendocrine, and metabolic function predict the psychological physical consequences depression in individuals, allowing for development new therapeutic targets with fewer side effects. Extensive research has included hundreds potential biomarkers depression, but their roles abnormal patients, how bioinformatics improve diagnosis, treatment, prognosis have not been determined or defined. To determine which cannot treatment response, classify patients specific treatments, develop interventions, proprietary strategies, current projects need tailored.

Language: Английский

---

Depression diagnostics using a nonlinear mathematical oscillatory model

Computer Methods and Programs in Biomedicine, Journal Year: 2024, Volume and Issue: 254, P. 108279 - 108279

Published: June 12, 2024

Language: Английский

---

Precision Psychiatry Approach to Treat Depression and Anxiety Targeting the Stress Hormone System – V1b-antagonists as a Case in Point

Pharmacopsychiatry, Journal Year: 2024, Volume and Issue: 57(06), P. 263 - 274

Published: Aug. 19, 2024

The future of depression pharmacotherapy lies in a precision medicine approach that recognizes is disease where different causalities drive symptoms. That calls for departure from current diagnostic categories, which are broad enough to allow adherence the "one-size-fits-all" paradigm, complementary routine use "broad-spectrum" mono-amine antidepressants. Similar oncology, narrowing overinclusive window by implementing laboratory tests, guide specifically targeted treatments, will be major step forward overcoming present drug discovery crisis.A substantial subgroup patients presents with signs and symptoms hypothalamic-pituitary-adrenocortical (HPA) overactivity. Therefore, this stress hormone system was considered offer worthwhile targets. Some promising results emerged, but sum, achieved targeting corticosteroid receptors were mixed.More specific non-peptidergic drugs block stress-responsive neuropeptides, corticotropin-releasing (CRH), arginine vasopressin (AVP) brain antagonizing their cognate CRHR1-and V1b-receptors. If patient's depressive symptomatology driven overactive V1b-signaling then V1b-receptor antagonist should first-line treatment. To identify patient having overactivity, neuroendocrine test, so-called dex/CRH-test, developed, indicates central AVP release too complicated routinely used. test transformed into gene-based "near-patient" allows immediate identification if depressed signaling. We believe next innovation depression.

Language: Английский

---

The influential factors of depression among caregivers of children with Cleft Lip and/or Palate: a path analysis based on diathesis-stress theoretical model

BMC Psychiatry, Journal Year: 2024, Volume and Issue: 24(1)

Published: Dec. 18, 2024

Depression is the most common psychological phenomenon among caregivers of children with Cleft Lip and/or Palate and affects quality life, treatment satisfaction, children's self-esteem parent–child relationship. However, Existing studies have limited explanations for mechanisms that lead to depression in Palate. The present study aimed identify factors influencing provide a reference point new ideas future research. This cross-sectional investigated 248 at two centers China, spanning from April 2019 July 2020. diathesis-stress model was used construct model, data analysis conducted using SPSS 26.0 AMOS 25.0. Path employed test hypothetical fit evaluated Chi-Square/degree freedom, Goodness-of-Fit Index, Normed Fit Relative Incremental Tacker-Lewis Comparative Index Root Mean Square Error Approximation. found average level 4.83 (4.79). Additionally, 43.5% exhibited depressive symptoms. modified path be satisfactory, following indices: freedom = 1.881, 0.986, 0.973, 0.919, 0.987, Tucker-Lewis 0.960, Approximation (RMSEA) 0.060. results indicated parenting stress had greatest direct impact on depression, followed by hope. Indirect effects were observed optimism, resilience, coping, which mediated through perceived social support stress. suggests leadingly influenced Strategies key are expected decrease depression.

Language: Английский

---

Vasoactive Substances as Mediators of Renal Injury

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

---